SCD5 and breast carcinoma: As a consequence of SPARC reduced secretion into the surrounding microenvironment, SCD5-transduced A375M melanoma and 4T1 mammary carcinoma cells, respectively injected into athymic Nu/Nu immunocompromised or immunocompetent syngeneic BALB/c mice were associated with decreased stromal deposition, eventually preventing their metastasization potential [9].